Claims
- 1. A compound of Formula (I) and its pharmaceutically acceptable acid addition salts or hydrates thereof
- 2. A compound of claim 1, wherein B is
- 3. A compound of claim 2 wherein Z is
- 4. A compound of claim 2 wherein Z is
- 5. A compound of claim 3 wherein R9 is
- 6. A compound of claim 1, wherein R1 and R4 are —CO2CH3.
- 7. The compound of claim 1 wherein n is 1, 2 or 3.
- 8. The compound of claim 1 wherein Z is
- 9. The compound of claim 1 wherein B is
- 10. The compound of claim 9 wherein R9 is 3-methyoxyphenyl or phenyl.
- 11. The compound of claim 1 wherein B is
- 12. The compound of claim 11 wherein Z is 3-methoxyphenylpiperidinyl.
- 13. The compound of claim 1 selected from the group consisting of
4-[3-[[[2-[4-(3-Methoxyphenyl)-1-piperidinyl]acetyl]hydrazino]carbonyl]amino]phenyl-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid, dimethyl ester; 4-[3-[[[2-[3-[4-(3-Methoxyphenyl)-1-piperidinyl]-1-oxopropyl]hydrazino]carbonyl]amino]phenyl-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid, dimethyl ester; 4-[3-[[[2-[4-[4-(3-Methoxyphenyl)-1-piperidinyl]-1-oxobutyl]hydrazino]carbonyl]amino]phenyl-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid, dimethyl ester; 4-[3-[[[2-[(4-Phenyl-1-piperidinyl)acetyl]-hydrazino]-carbonyl]amino]phenyl]1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid, dimethyl ester; 4-[3-[[[2-[(4-Phenyl-1-piperidinyl)acetyl]-hydrazino]-carbonothioyl]amino]phenyl]1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid, dimethyl ester; 4-[3-[[[2-[[4-(3-Methoxyphenyl)-1-piperidinyl)acetyl]-hydrazino]-carbonothioyl]amino]phenyl]1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid, dimethyl ester; 4-[3-[[[2-[(4-Phenyl)-1-piperazinyl]acetyl]-hydrazino]-carbonothioyl]amino]phenyl]1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid, dimethyl ester; 4-[4-Fluoro-3-[[[2-[[4-(3-methoxyphenyl)-1-piperidinyl]acetyl]-hydrazino]-carbonothioyl]amino]phenyl]1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid, dimethyl ester; 4-[3-[[[2-[[4-(1-Piperidinyl)-1-piperidinyl]acetyl]-hydrazino]-carbonothioyl]amino]phenyl]1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid, dimethyl ester; and 4-[3-[[[2-[(4-Cyclohexyl-1-piperazinyl) acetyl]-hydrazino]-carbonothioyl]amino]phenyl]1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid, dimethyl ester.
- 14. The compound of claim 1 selected from the group consisting of
4-[3-[[5-[4-(Methoxyphenyl)-1-piperidinyl]methyl]-1,3,4-oxadiazol-2-yl]amino]phenyl]-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate, hydrochloride salt; 4-[3-[[5-[4-(3-Methoxyphenyl)-1-piperidinyl]ethyl]-1,3,4-oxadiazol-2-yl]amino]phenyl]-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate, hydrochloride salt; and 4-[3-[[5-[3-[4-(3-Methoxyphenyl)-1-piperidinyl]propyl]-1,3,4-oxadiazol-2-yl]amino]phenyl]-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate, hydrochloride salt.
- 15. The compound of claim 1 selected from the group consisting of
4-[3-[[5-[(4-Phenyl-1-piperidinyl)methyl]-1,3,4-oxadiazol-2-yl]amino]phenyl]-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate; 4-[3-[[5-[(4-Phenyl-1-piperazinyl)methyl]-1,3,4-oxadiazol-2-yl]amino]phenyl]-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate; 4-[3-[[5-[(4-Cyclohexyl-1-piperazinyl)methyl]-1,3,4-oxadiazol-2-yl]amino]phenyl]-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate; 4-[-fluoro-3-[[5-[[4-(3-Methoxyphenyl-1-piperidinyl)methyl]-1,3,4-oxadiazol-2-yl]amino]phenyl]-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate; and 4-[3-[[5-[(4-Piperdine-1-piperidinyl)methyl]-1,3,4-oxadiazol-2-yl]amino]phenyl]-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate.
- 16. The compound of claim 1 selected from the group consisting of
4-[3-[[5-[(4-Phenyl-1-piperidinyl)methyl]-1,3,4-thiadiazol-2-yl]amino]phenyl]-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate; (±) 1,4-Dihydro-4-[3-[[4-(ethoxy) 1,2,5-thiadiaz-3-ole-1-oxide]amino]phenyl]-2,6-dimethyl-3,5-pyridinedicarboxylic acid, hemihydrate; and (±)4-[3-[[3-[[4-(3-Methoxyphenyl)-1-piperidinyl]propyl]amino]1,2,5-thiadiaz-2-ole-1-oxide]amino]phenyl]-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid, dimethyl ester, dihydrate.
- 17. A method of promoting weight loss and treating eating disorders in a mammal comprising administering to a mammalian host an anorexiant effective dose of a compound claimed in claim 1.
- 18. A method of treating clinical disorders amenable to alleviation by eliciting an NPY Y1 response, comprising administering to a patient suffering from such a disorder an effective amount of a compound claimed in claim 1.
- 19. A pharmaceutical composition for use in promoting weight loss and treating eating disorders, the composition comprising an anorexiant effective amount of a compound claimed in claim 1 in combination with a pharmaceutically acceptable carrier.
CROSS REFERENCE TO RELATED APPLICATION
[0001] This non-provisional application claims priority from provisional application U.S. Ser. No. 60/216,985 filed Jul. 7, 2000.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60216985 |
Jul 2000 |
US |